Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• The tumor suppressor p53 (TP53) is crucial for preventing cancer and is often inactivated in tumors.
• MDM2 negatively regulates p53 via a feedback loop, making it a therapeutic target.
• Restoring p53 function by inhibiting MDM2 is a key strategy in anticancer drug development.

Purpose of the Study:

• To review the discovery, structural modifications, and clinical progress of MDM2 inhibitors.
• To analyze challenges in clinical development and propose future strategies for MDM2-targeted therapies.

Main Methods:

• Literature review of MDM2 inhibitors.
• Analysis of medicinal chemistry approaches.
• Evaluation of preclinical and clinical data.

Main Results:

• Nine structurally diverse MDM2 inhibitors have entered clinical trials.
• No MDM2 inhibitor has yet received clinical approval.
• Clinical development faces challenges, including dose-dependent toxicity.

Conclusions:

• MDM2 inhibitors hold promise but require optimization for clinical efficacy and safety.
• Multitarget or targeted degradation strategies may overcome current limitations.
• Future agents targeting the p53-MDM2 interaction could improve anti-tumor activity and reduce toxicity.